VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2022 | Real-world analysis of gilteritinib for R/R FLT3-mutated AML

Shai Shimony, MD, Dana-Farber Cancer Institute, Boston, MA, shares some key results from a real-world analysis of gilteritinib for the treatment of relapsed/refractory (R/R) FLT3-mutated acute myeloid leukemia (AML). Dr Shimony discusses the overall survival (OS) observed in patients and the efficacy of this agent, as well as the importance of investigating other treatment combinations in the future. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter